Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

230
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
230
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

354
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
354
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

415
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
415
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

430
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
430
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

379
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
379

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lung Cancer Screening Eligibility in the Community: Cardiovascular Risk Factors, Coronary Artery Calcification, and Cardiovascular Events.

Circulation·2016
Same author

The Impact of Hospice Services in the Care of Patients with Advanced Stage Nonsmall Cell Lung Cancer.

Journal of palliative medicine·2016
Same author

Progressive 3-Month Increase in LV Myocardial ECV After Anthracycline-Based Chemotherapy.

JACC. Cardiovascular imaging·2016
Same author

Adjuvanting an inactivated influenza vaccine with flagellin improves the function and quantity of the long-term antibody response in a nonhuman primate neonate model.

Vaccine·2016
Same author

Anthracycline-Associated T1 Mapping Characteristics Are Elevated Independent of the Presence of Cardiovascular Comorbidities in Cancer Survivors.

Circulation. Cardiovascular imaging·2016
Same author

No One Size Fits All: Scoring Risk of In-Hospital Death After Myocardial Infarction.

Journal of the American College of Cardiology·2016

Related Experiment Video

Updated: Apr 27, 2026

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

4.6K

Multiplicity adjustments in testing for bioequivalence.

Steven Y Hua1, Siyan Xu, Ralph B D'Agostino

  • 1Pfizer Inc., Biotechnology Clinical Development, 10777 Science Center Dr., San Diego, CA, 92121, U.S.A.

Statistics in Medicine
|July 2, 2014
PubMed
Summary
This summary is machine-generated.

Ensuring drug bioequivalence requires simultaneous control of area under the concentration-time curve (AUC) and maximum concentration (Cmax). New methods, a closed test procedure and alpha-adaptive sequential testing (AAST), effectively manage statistical error rates for robust bioequivalence assessment.

Keywords:
FWERTOSTalpha-adaptive procedurebioequivalenceclosed testmultiplicity adjustment

More Related Videos

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

21.0K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

9.2K

Related Experiment Videos

Last Updated: Apr 27, 2026

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

4.6K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

21.0K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

9.2K

Area of Science:

  • Pharmacometrics
  • Drug Development
  • Biostatistics

Background:

  • Bioequivalence assessment typically involves two one-sided tests for pharmacokinetic parameters like area under the concentration-time curve (AUC) and maximum concentration (Cmax).
  • Simultaneous equivalence testing across multiple parameters can inflate the family-wise error rate (FWER) if multiplicity is not addressed.
  • The multiplicity issue in simultaneous bioequivalence testing is an under-discussed area in scientific literature.

Purpose of the Study:

  • To propose novel statistical approaches for controlling the family-wise error rate (FWER) in simultaneous bioequivalence testing of AUC and Cmax.
  • To introduce a closed test procedure and an alpha-adaptive sequential testing (AAST) method for robust bioequivalence assessment.
  • To compare the proposed methods against traditional multiplicity adjustment techniques like Bonferroni correction.

Main Methods:

  • A closed test procedure is presented to control FWER for simultaneous AUC and Cmax bioequivalence without type-I error adjustment.
  • An alpha-adaptive sequential testing (AAST) approach is developed, adaptively controlling FWER by setting significance levels for AUC (α1) and Cmax (α2).
  • Both methods were illustrated using published data and compared to standard statistical adjustments.

Main Results:

  • Both the closed test procedure and AAST effectively control the FWER in simultaneous bioequivalence testing.
  • The closed test involves testing eight intersection null hypotheses at the α level.
  • AAST controls FWER by adaptively adjusting significance levels, potentially prioritizing AUC equivalence, and offers an alternative to Bonferroni adjustments.

Conclusions:

  • The proposed closed test procedure and AAST offer statistically sound methods for ensuring simultaneous bioequivalence of AUC and Cmax.
  • These novel approaches provide better control over FWER compared to traditional methods like Bonferroni adjustment.
  • Despite operational differences, both methods can yield consistent conclusions and enhance the reliability of bioequivalence studies.